Paul MD - Sana Biotechnology Senior Science
| SANA Stock | USD 2.48 0.13 4.98% |
Executive
Paul MD is Senior Science of Sana Biotechnology
| Address | 188 East Blaine Street, Seattle, WA, United States, 98102 |
| Phone | 206 701 7914 |
| Web | https://www.sana.com |
Sana Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.3115) % which means that it has lost $0.3115 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.929) %, meaning that it created substantial loss on money invested by shareholders. Sana Biotechnology's management efficiency ratios could be used to measure how well Sana Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.81. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Sana Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 361.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 6.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jasmin Tower | Generation Bio Co | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Adrian MD | Zentalis Pharmaceuticals Llc | N/A | |
| Mary CPA | Cullinan Oncology LLC | 60 | |
| Pr MD | Apellis Pharmaceuticals | N/A | |
| Alicia Hager | Nkarta Inc | 54 | |
| Roman Necina | Hookipa Pharma | 56 | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Juliet BA | Kymera Therapeutics | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| JD Esq | Kymera Therapeutics | 65 | |
| Geoffrey Mogilner | Olema Pharmaceuticals | N/A | |
| Michael CPA | Blueprint Medicines Corp | 52 | |
| Moriarty ESQ | Olema Pharmaceuticals | 56 | |
| Ellen Rose | Lyell Immunopharma | N/A | |
| Ingmar MD | Zentalis Pharmaceuticals Llc | 49 | |
| Xiaolin Wang | Revolution Medicines | 53 | |
Management Performance
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.31 |
Sana Biotechnology Leadership Team
Elected by the shareholders, the Sana Biotechnology's board of directors comprises two types of representatives: Sana Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sana. The board's role is to monitor Sana Biotechnology's management team and ensure that shareholders' interests are well served. Sana Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sana Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sunil MD, Head VP | ||
| Christian MBA, Executive Officer | ||
| Shanna Peek, Sr Operations | ||
| Richard Mulligan, Executive Research | ||
| Nathan MBA, Executive CFO | ||
| Sonja MD, Senior Platform | ||
| Susan Wyrick, Treasurer, CFO | ||
| Gary MD, Chief Officer | ||
| Farah Anwar, Head Operations | ||
| John MD, Head Development | ||
| Terry MD, Senior Therapeutics | ||
| Yuko JD, Head Property | ||
| Snehal Patel, Senior Officer | ||
| Paul MD, Senior Science | ||
| Steven MD, CEO President | ||
| Edward Rebar, Head Engineering | ||
| Brittany Mccleery, Accounting Mang | ||
| Robin Andrulevich, Executive Officer | ||
| Bernard JD, Exec Counsel |
Sana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sana Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 479.81 M | ||||
| Shares Outstanding | 223.27 M | ||||
| Shares Owned By Insiders | 8.63 % | ||||
| Shares Owned By Institutions | 92.40 % | ||||
| Number Of Shares Shorted | 34.28 M | ||||
| Price To Book | 1.99 X | ||||
| EBITDA | (252.39 M) | ||||
| Net Income | (283.25 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.